trump rx glp 1 drug price deal: Burning questions after Lilly, Novo agreement Trump announces deal to sell
Description
The kidney and cardiovascular outcome trials
Acute kidney injury associated with semaglutide
Further studies are needed to investigate the bone impact of GLP-1Ra, dual- and triple-receptor agonists for GLP-1, glucose-dependent insulin releasing polypeptide (GIP), and glucagon in PwO
doi: 10.1016/0167-4889(84)90071-5
Discontinuation rates undermined the value argument Cost alone might not have tipped the scales
Considering the large variety of therapies available, each with different attributes and mechanisms of action, along with the heterogenous nature of T2DM, the treatment landscape is understandably complicated
